Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of LY4065967 in Healthy Japanese Participants

← catalyst calendar

NCT06594159

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
59actual
Sites
1
Country
Japan

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-10-22actualWhen the study began enrolling
Primary completion2025-03-11actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-03-11actualThe whole study's end, after follow-up
First posted2024-09-19actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-04-03actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Healthy

Interventions

  • Drug: LY4065967
  • Drug: Placebo
  • Drug: Rosuvastatin

Primary outcomes

what the primary-completion date above is the date OF
Part A: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
measured Baseline to 7 Days
Part B: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered to be Related to Study Drug Administration
measured Baseline to 12 Days
Part D: PK: Maximum Concentration (Cmax) of Rosuvastatin
measured Predose on Day 1 Through 72 Hours Post-Dose
Part D: PK: Area Under the Concentration Versus Time Curve (AUC) of Rosuvastatin
measured Predose on Day 1 Through 72 Hours Post-Dose

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed